よむ、つかう、まなぶ。
【参考資料２－１】抗微生物薬適正使用の手引き 第四版（案）医科・外来編 (52 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
医科・外来編
103. Rockx B, et al. Natural history of human calicivirus infection: a prospective cohort study. Clin
Infect Dis. 2002. 35:246-53.
104. Lopman BA, et al. Clinical manifestation of norovirus gastroenteritis in health care settings.
Clin Infect Dis. 2004. 39:318-24.
105. 山崎勉, 他. イムノクロマト法による便中ノロウイルス検出キットの評価 ―検体種による差
の検討―. 感染症学会雑誌. 2016. 90:92-5.
106. Tajiri H, et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic
syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob
Agents. 2015. 46:586-9.
107. Kelly P. Infectious diarrhoea. Medicine. 2011. 39:201-6.
108. Bell BP, et al. Predictors of Hemolytic Uremic Syndrome in Children During a Large Outbreak
of Escherichia coli O157:H7 Infections. Pediatrics. 1997. 100:e12-e.
109. National Institute for Health and Care Excellence (NICE). Respiratory tract infections (selflimiting): prescribing antibiotics | Clinical guideline. 2008. [Available from:
https://www.nice.org.uk/guidance/cg69?unlid=345604181201722763.
110. ファクトシート（科学的知見に基づく概要書） 内品. [Available from:
https://www.fsc.go.jp/factsheets/.
111. Caeiro JP, et al. Oral rehydration therapy plus loperamide versus loperamide alone in the
treatment of traveler's diarrhea. Clin Infect Dis. 1999. 28:1286-9.
112. Onwuezobe IA, et al. Antimicrobials for treating symptomatic non-typhoidal Salmonella
infection. Cochrane Database Syst Rev. 2012. 11:CD001167.
113. DuPont HL. Bacterial diarrhea. N Engl J Med. 2009. 361:1560-9.
114. 感染症治療ガイド・ガイドライン作成委員会編 JJ. XVI 腸管感染症. JAID/JSC 感染症治療
ガイドライン 2023. 東京: 杏林舎; 2023. p. 366-73.
115. Ternhag A, et al. A meta-analysis on the effects of antibiotic treatment on duration of
symptoms caused by infection with Campylobacter species. Clin Infect Dis. 2007. 44:696700.
116. Freedman SB, et al. Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk
of Developing Hemolytic Uremic Syndrome: A Meta-analysis. Clin Infect Dis. 2016. 62:12518.
117. Ikeda K, et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic
syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol. 1999. 52:357-62.
118. Myojin S, et al. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and
risk of hemolytic uremic syndrome: A population-based matched case control study. PLOS
ONE. 2022. 17:e0263349.
119. 国際的に脅威となる感染症対策関係閣僚会議. 薬剤耐性(AMR)対策アクションプラン 20232027. 東京: 内閣官房; 2023.
https://www.cas.go.jp/jp/seisaku/zensedai_hosyo/dai19/02_siryou2.pdf
120. Kate E, et al. Admission avoidance hospital at home. Cochrane Database Syst Rev. 2024.
2024(3):CD007491.
121. Gonçalves-Bradley DC, et al. Early discharge hospital at home. Cochrane Database Syst
Rev. 2017. 2017(6):CD000356.
122. World Health Organization. WHO AWaRe Classification Database of Antibiotics for
Evaluation and Monitoring of Use. https://aware.essentialmeds.org/groups （最終閲覧日
2025 年 4 月 9 日）
52
第四版
医科・外来編
103. Rockx B, et al. Natural history of human calicivirus infection: a prospective cohort study. Clin
Infect Dis. 2002. 35:246-53.
104. Lopman BA, et al. Clinical manifestation of norovirus gastroenteritis in health care settings.
Clin Infect Dis. 2004. 39:318-24.
105. 山崎勉, 他. イムノクロマト法による便中ノロウイルス検出キットの評価 ―検体種による差
の検討―. 感染症学会雑誌. 2016. 90:92-5.
106. Tajiri H, et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic
syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob
Agents. 2015. 46:586-9.
107. Kelly P. Infectious diarrhoea. Medicine. 2011. 39:201-6.
108. Bell BP, et al. Predictors of Hemolytic Uremic Syndrome in Children During a Large Outbreak
of Escherichia coli O157:H7 Infections. Pediatrics. 1997. 100:e12-e.
109. National Institute for Health and Care Excellence (NICE). Respiratory tract infections (selflimiting): prescribing antibiotics | Clinical guideline. 2008. [Available from:
https://www.nice.org.uk/guidance/cg69?unlid=345604181201722763.
110. ファクトシート（科学的知見に基づく概要書） 内品. [Available from:
https://www.fsc.go.jp/factsheets/.
111. Caeiro JP, et al. Oral rehydration therapy plus loperamide versus loperamide alone in the
treatment of traveler's diarrhea. Clin Infect Dis. 1999. 28:1286-9.
112. Onwuezobe IA, et al. Antimicrobials for treating symptomatic non-typhoidal Salmonella
infection. Cochrane Database Syst Rev. 2012. 11:CD001167.
113. DuPont HL. Bacterial diarrhea. N Engl J Med. 2009. 361:1560-9.
114. 感染症治療ガイド・ガイドライン作成委員会編 JJ. XVI 腸管感染症. JAID/JSC 感染症治療
ガイドライン 2023. 東京: 杏林舎; 2023. p. 366-73.
115. Ternhag A, et al. A meta-analysis on the effects of antibiotic treatment on duration of
symptoms caused by infection with Campylobacter species. Clin Infect Dis. 2007. 44:696700.
116. Freedman SB, et al. Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk
of Developing Hemolytic Uremic Syndrome: A Meta-analysis. Clin Infect Dis. 2016. 62:12518.
117. Ikeda K, et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic
syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol. 1999. 52:357-62.
118. Myojin S, et al. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and
risk of hemolytic uremic syndrome: A population-based matched case control study. PLOS
ONE. 2022. 17:e0263349.
119. 国際的に脅威となる感染症対策関係閣僚会議. 薬剤耐性(AMR)対策アクションプラン 20232027. 東京: 内閣官房; 2023.
https://www.cas.go.jp/jp/seisaku/zensedai_hosyo/dai19/02_siryou2.pdf
120. Kate E, et al. Admission avoidance hospital at home. Cochrane Database Syst Rev. 2024.
2024(3):CD007491.
121. Gonçalves-Bradley DC, et al. Early discharge hospital at home. Cochrane Database Syst
Rev. 2017. 2017(6):CD000356.
122. World Health Organization. WHO AWaRe Classification Database of Antibiotics for
Evaluation and Monitoring of Use. https://aware.essentialmeds.org/groups （最終閲覧日
2025 年 4 月 9 日）
52